Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationDeep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipientsHCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, BrazilModeling viral evolutionary dynamics after telaprevir-based treatmentSimilar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencingNatural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in ChinaGlobal prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataNaturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve PatientsHepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfectionHepatitis C virus NS5A inhibitors and drug resistance mutations.Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/RibavirinUltradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody.Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Secondary Structural Elements of the HCV X-region Involved in Viral ReplicationPre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort.Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor TherapyInvestigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitorNonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.Prevention and management of treatment failure to new oral hepatitis C drugs.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.Hepatitis C virus resistance to the new direct-acting antivirals.Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
P2860
Q24628717-99155BA6-1EBD-4542-BEE9-2515ED3EB98CQ26783056-03168289-C304-4CA9-9CC7-BA22BD3A8B0DQ28079102-AEE10944-BAEC-4934-8F82-7A6310C3B513Q28534965-C7279951-3E5C-4FF2-8CF9-5E32D079CDEBQ28538943-3691C847-B721-412E-9C14-A196FF82A8F6Q28542375-8DC01849-6890-4818-9D8A-45377483D380Q28542443-8639B488-0AA6-4E69-B59B-34634191A5A6Q28552134-41216093-DEEF-4333-971E-0B58F6FC8937Q31042796-4C926EF8-6E23-4688-B1B4-C015B456079CQ33672648-1D590351-E974-49AB-AB19-C5339B04EBECQ33875539-7FDD9C37-B6FA-4521-A643-FFDCDC2EF9DFQ34298877-17D204D3-AE7A-4199-B424-BE30BAE9BC4BQ34411617-6EA616C9-8631-4EE6-AB26-22C81BFE07E8Q34802167-8368A4E8-93CE-4347-A8F9-EA7907958D9AQ34983102-930DEF41-2EFF-484F-B118-A192C54ACC8AQ35193285-449265CE-B405-4987-A163-D794A31C774AQ35735285-815C6521-AD3C-4236-B9D3-AC510619C79DQ35757761-18921019-FA80-4CB8-AF12-B681798CE01FQ35759025-17C5A565-C912-4C9F-B9ED-5FA7D29ECECAQ35972684-71D6ADC2-481B-43DF-B30F-26604BF349E2Q36182240-BA79AEE7-C3C4-4E2E-9AFF-D346BD114E29Q36292486-C050C390-BC07-475F-8084-80CD777875CFQ36506480-0E37B5CB-7450-4A77-82CC-08B31CF87AA5Q36881967-FD23FABC-B4E8-46FA-9A71-B58FACFC7700Q36988456-54531CD0-18C8-499F-973F-0038C0B535A5Q37373261-436E527D-AB00-44BF-8BEB-5A454572E369Q37426527-9A4C029E-5CC1-497A-A0D7-CB9F9BF2E6E2Q37615174-DA6DB70D-14A6-4235-BF6B-A1AB19AD84F1Q37738808-B0E98304-274B-4C5B-B03B-6C7F39B47393Q38193551-A333DFF2-F35F-43CB-974A-B57709A752AAQ38427538-BCCCC763-6FA3-46B5-A6BE-9DE41C4CA237Q38611842-E52C4623-776E-4F6D-86EB-603508CF9265Q38779980-929EF593-F587-4819-93B2-194C06B630D0Q38826624-49367C17-8949-4561-87AA-A011577328E3Q38849307-D9BF210F-6E01-46C7-9AC7-26A149D79AC8Q38864459-F3B82427-DCD8-4545-88FE-2BF3055134F1Q38887954-AD000A41-569B-4116-A54C-531D022D3950Q38972180-7F1A0C70-1D17-45D6-9801-615D2BA74463Q38992902-2B83CE3A-9707-4753-BC09-D601801691A4Q39020651-301707AE-E326-47B2-BE02-0974EEE33367
P2860
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Hepatitis C virus variants wit ...... e patients prior to treatment.
@en
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals
@nl
type
label
Hepatitis C virus variants wit ...... e patients prior to treatment.
@en
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals
@nl
prefLabel
Hepatitis C virus variants wit ...... e patients prior to treatment.
@en
Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals
@nl
P2093
P2860
P356
P1433
P1476
Hepatitis C virus variants wit ...... e patients prior to treatment.
@en
P2093
Ann D Kwong
Ann M Tigges
Darin Takemoto
Doug J Bartels
Eileen Z Zhang
Elizabeth Dondero
Gaston Picchio
James C Sullivan
Jennifer L Dorrian
Sandra De Meyer
P2860
P304
P356
10.1128/JVI.02294-12
P407
P577
2012-11-14T00:00:00Z